{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:33:30Z","timestamp":1791113610550,"version":"4.1.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.2215\/cjn.09421209","type":"journal-article","created":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T22:15:19Z","timestamp":1275603319000},"page":"1380-1387","source":"Crossref","is-referenced-by-count":87,"title":["A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Carotid Intima-Media Thickness in Nondiabetic Hemodialysis Patients"],"prefix":"10.2215","volume":"5","author":[{"given":"Antonio","family":"Vukusich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Kunstmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Varela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gainza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Sepulveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Cavada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Michea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa T.","family":"Marusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20230601","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/ndt\/15.suppl_5.97","article-title":"Cardiovascular risk in end-stage renal disease: Vascular aspects","volume":"15","author":"London","year":"2007","journal-title":"Nephrol Dial Transplant"},{"key":"R2-6-20230601","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/CIRCULATIONAHA.106.678342","article-title":"Chronic kidney disease: Effects on the cardiovascular system","volume":"116","author":"Schiffrin","year":"2007","journal-title":"Circulation"},{"key":"R3-6-20230601","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0272-6386(12)80827-4","article-title":"Cardiovascular risk factors in chronic renal failure and hemodialysis populations","volume":"19","author":"Ma","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"R4-6-20230601","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1056\/NEJM199604113341502","article-title":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","volume":"334","author":"Maschio","year":"1996","journal-title":"N Engl J Med"},{"key":"R5-6-20230601","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/j.1523-1755.2005.00145.x","article-title":"Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: Pathophysiology and indications","volume":"67","author":"Wolf","year":"2005","journal-title":"Kidney Int"},{"key":"R6-6-20230601","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF00877755","article-title":"\u201cEscape\u201d of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy","volume":"9","author":"Pitt","year":"1995","journal-title":"Cardiovasc Drugs Ther"},{"key":"R7-6-20230601","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","article-title":"Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker","volume":"1","author":"Chrysostomou","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R8-6-20230601","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R9-6-20230601","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: A systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-6-20230601","first-page":"2985","article-title":"Common carotid artery intima-media thickness and the risk of stroke recurrence","volume":"34","author":"Tsivgoulis","year":"2003","journal-title":"Stroke"},{"key":"R11-6-20230601","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1161\/01.CIR.96.5.1432","article-title":"Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study","volume":"96","author":"Bots","year":"1997","journal-title":"Circulation"},{"key":"R12-6-20230601","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1056\/NEJM199901073400103","article-title":"Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults","volume":"340","author":"O'Leary","year":"1999","journal-title":"N Engl J Med"},{"key":"R13-6-20230601","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1161\/CIRCULATIONAHA.106.628875","article-title":"Prediction of clinical cardiovascular events with carotid intima-media thickness: A systematic review and meta-analysis","volume":"30","author":"Lorenz","year":"2007","journal-title":"Circulation"},{"key":"R14-6-20230601","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.atherosclerosis.2008.05.051","article-title":"Intima-media thickness is a useful marker of the extent of coronary artery disease in patients with impaired renal function","volume":"202","author":"Lisowska","year":"2009","journal-title":"Atherosclerosis"},{"key":"R15-6-20230601","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2215\/CJN.03670807","article-title":"Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle?","volume":"3","author":"Stenvinkel","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"R16-6-20230601","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1053\/j.ajkd.2005.07.048","article-title":"Association between carotid artery intima-media thickness and cardiovascular risk factors in CKD","volume":"46","author":"Preston","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"R17-6-20230601","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.amjcard.2008.02.060","article-title":"Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease","volume":"101","author":"Shishehbor","year":"2008","journal-title":"Am J Cardiol"},{"key":"R18-6-20230601","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"R19-6-20230601","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2215\/CJN.00120106","article-title":"Aldosterone antagonism in chronic kidney disease","volume":"1","author":"Ponda","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R20-6-20230601","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.amjmed.2006.03.038","article-title":"Aldosterone blockade: An emerging strategy for abrogating progressive renal disease","volume":"119","author":"Epstein","year":"2006","journal-title":"Am J Med"},{"key":"R21-6-20230601","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: A mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"key":"R22-6-20230601","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.amjcard.2005.06.059","article-title":"Gender differences in carotid intima-media thickness in patients with suspected coronary artery disease","volume":"96","author":"Kablak-Ziembicka","year":"2005","journal-title":"Am J Cardiol"},{"key":"R23-6-20230601","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjmed.2007.08.038","article-title":"CARMELA: Assessment of cardiovascular risk in seven Latin American cities","volume":"121","author":"Schargrodsky","year":"2008","journal-title":"Am J Med"},{"key":"R24-6-20230601","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1093\/ndt\/gfm906","article-title":"Carotid artery intima-media thickness correlates with oxidative stress in chronic hemodialysis patients with accelerated atherosclerosis","volume":"23","author":"Dursun","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"R25-6-20230601","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2215\/CJN.01840408","article-title":"Atheroma progression in chronic kidney disease","volume":"4","author":"Rigatto","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R26-6-20230601","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1053\/j.ajkd.2007.11.026","article-title":"Kidney function and progression of carotid intima-media thickness in a community study","volume":"51","author":"Desbien","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R27-6-20230601","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1001\/archinte.163.15.1837","article-title":"Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: Treatment with simvastatin","volume":"163","author":"Nolting","year":"2003","journal-title":"Arch Intern Med"},{"key":"R28-6-20230601","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2009.01.039","article-title":"Aldosterone blockade by spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice","volume":"206","author":"Sakurabayashi-Kitade","year":"2009","journal-title":"Atherosclerosis"},{"key":"R29-6-20230601","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/HYPERTENSIONAHA.108.125252","article-title":"Mechanisms of impaired potassium handling with dual renin-angiotensin-aldosterone blockade in chronic kidney disease","volume":"53","author":"Preston","year":"2009","journal-title":"Hypertension"},{"key":"R30-6-20230601","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1001\/jama.1980.03310220049028","article-title":"Hyperkalemia resulting from captopril administration","volume":"244","author":"Warren","year":"1980","journal-title":"JAMA"},{"key":"R31-6-20230601","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","article-title":"Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system","volume":"351","author":"Palmer","year":"2004","journal-title":"N Engl J Med"},{"key":"R32-6-20230601","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1523-1755.2004.00931.x","article-title":"Effect of spironolactone on K + homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients","volume":"66","author":"Michea","year":"2004","journal-title":"Kidney Int"},{"key":"R33-6-20230601","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/ndt\/gfk086","article-title":"It is time for spironolactone therapy in dialysis patients?","volume":"21","author":"Covic","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"R34-6-20230601","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1053\/j.ajkd.2005.03.005","article-title":"Effect of spironolactone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric hemodialysis patients","volume":"46","author":"Gross","year":"2005","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201008000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:39:49Z","timestamp":1786369189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201008000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.09421209","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}